Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hi-Tech

This article was originally published in The Tan Sheet

Executive Summary

Health care products division to launch DiabetiSpray throat spray and DiabetiDerm moisturizer with urea, company announces July 26. Throat spray will reach shelves nationwide in time for fall cold season, with moisturizer soon to follow. Company working on direct-to-consumer marketing via mail-order catalog launched last spring, potential online catalog. Previous strategy targeted pharmacists, physicians and diabetic educators. Revamping efforts aim to build on Hi-Tech record sales of $29.6 mil., up 5.7% in fiscal 2001 (ended April 30). Year-end net income jumped 41% to $2.4 mil. Health care product sales, led by sugar-free cough syrup DiabetiTussin, comprised roughly 20% of total

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel